陕西中医
陝西中醫
협서중의
Shaanxi Journal of Traditional Chinese Medicine
2015年
11期
1450-1452
,共3页
乙型肝炎,慢性%肝纤维化/中医药疗法%益气活血解毒方
乙型肝炎,慢性%肝纖維化/中醫藥療法%益氣活血解毒方
을형간염,만성%간섬유화/중의약요법%익기활혈해독방
Hepatitis B,chronic%Liver fibrosis/traditional%Chinese medicine therapy%Yiqi Huoxue%Jiedu decoction
目的：：探讨慢性病毒性乙型肝炎肝纤维化行自拟益气活血解毒方治疗临床效果,为临床选择治疗方式提供参考。方法：将慢性病毒性乙型肝炎肝纤维化患者,按照数字表法分为对照组与治疗组各40例。对照组采用基础治疗,治疗组在对照组基础上联合益气活血解毒化痰的中药治疗,对比两组患者治疗前后中医证候积分、血清肝纤维化指标、肝功能指标、超声影像学指标。结果：治疗后治疗组 LN、HA、Ⅳ-C 分别为113.44±16.55μg/L、172.28±23.35μg/L、143.33±18.84μg/L,均明显优于对照组,对比差异有统计学意义(t=7.994,P=0.002；t=14.214,P=0.000；t=10.514,P=0.000)；治疗后治疗组 Alb、TBil、ALT、AST 分别为43.94±5.61 g/L、12.28±2.27μmol/L、64.06±8.11 U/L、38.14±5.34 U/L,均优于对照组,对比差异有统计学意义(t=5.247,P=0.015；t=6.347,P=0.008；t=6.137,P=0.009；t=4.995,P=0.018)；治疗后治疗组中医证候积分为5.23±0.67,明显低于对照组,对比差异有统计学意义(t=6.664,P=0.007),治疗组与对照组门静脉直径、脾肿指数治疗前后组内对比差异有统计学意义(P<0.05)。结论：益气活血解毒方可有效改善慢性病毒性乙型肝炎肝纤维化患者纤维化进展及临床症状。
目的：：探討慢性病毒性乙型肝炎肝纖維化行自擬益氣活血解毒方治療臨床效果,為臨床選擇治療方式提供參攷。方法：將慢性病毒性乙型肝炎肝纖維化患者,按照數字錶法分為對照組與治療組各40例。對照組採用基礎治療,治療組在對照組基礎上聯閤益氣活血解毒化痰的中藥治療,對比兩組患者治療前後中醫證候積分、血清肝纖維化指標、肝功能指標、超聲影像學指標。結果：治療後治療組 LN、HA、Ⅳ-C 分彆為113.44±16.55μg/L、172.28±23.35μg/L、143.33±18.84μg/L,均明顯優于對照組,對比差異有統計學意義(t=7.994,P=0.002；t=14.214,P=0.000；t=10.514,P=0.000)；治療後治療組 Alb、TBil、ALT、AST 分彆為43.94±5.61 g/L、12.28±2.27μmol/L、64.06±8.11 U/L、38.14±5.34 U/L,均優于對照組,對比差異有統計學意義(t=5.247,P=0.015；t=6.347,P=0.008；t=6.137,P=0.009；t=4.995,P=0.018)；治療後治療組中醫證候積分為5.23±0.67,明顯低于對照組,對比差異有統計學意義(t=6.664,P=0.007),治療組與對照組門靜脈直徑、脾腫指數治療前後組內對比差異有統計學意義(P<0.05)。結論：益氣活血解毒方可有效改善慢性病毒性乙型肝炎肝纖維化患者纖維化進展及臨床癥狀。
목적：：탐토만성병독성을형간염간섬유화행자의익기활혈해독방치료림상효과,위림상선택치료방식제공삼고。방법：장만성병독성을형간염간섬유화환자,안조수자표법분위대조조여치료조각40례。대조조채용기출치료,치료조재대조조기출상연합익기활혈해독화담적중약치료,대비량조환자치료전후중의증후적분、혈청간섬유화지표、간공능지표、초성영상학지표。결과：치료후치료조 LN、HA、Ⅳ-C 분별위113.44±16.55μg/L、172.28±23.35μg/L、143.33±18.84μg/L,균명현우우대조조,대비차이유통계학의의(t=7.994,P=0.002；t=14.214,P=0.000；t=10.514,P=0.000)；치료후치료조 Alb、TBil、ALT、AST 분별위43.94±5.61 g/L、12.28±2.27μmol/L、64.06±8.11 U/L、38.14±5.34 U/L,균우우대조조,대비차이유통계학의의(t=5.247,P=0.015；t=6.347,P=0.008；t=6.137,P=0.009；t=4.995,P=0.018)；치료후치료조중의증후적분위5.23±0.67,명현저우대조조,대비차이유통계학의의(t=6.664,P=0.007),치료조여대조조문정맥직경、비종지수치료전후조내대비차이유통계학의의(P<0.05)。결론：익기활혈해독방가유효개선만성병독성을형간염간섬유화환자섬유화진전급림상증상。
Objective:To investigate effectiveness of Yiqi Huoxue Jiedu decoction treatment for chronic vi-ral hepatitis B fibrosis patients,to provide a reference for clinical treatment.Methods:80 cases of hepatic fibrosis with chronic toxicity patients were selected,they were divided into control group and observation group,40 cases each.The control group was treated with basic treatment,observation group was treated with Yiqi Huoxue Jiedu decoction treatment on base of treatment of control group,two groups of patients before and after treatment symptom scores,ser-um liver fibrosis,liver function,ultrasound imaging targets were compared.Results:After treatment observation group’ s LN,HA,Ⅳ-C were 113.44 ± 16.55μg/L,172.28 ± 23.35μg/L,143.33 ± 18.84μg/L,significantly better than the control group,the difference was statistically significant(t= 7.994,P = 0.002;t= 14.214,P = 0.000;t= 10. 514,P=0.000);after treatment observation group's Alb,TBil,ALT,AST was 43.94 ± 5.61 g/L,12.28 ± 2. 27μmol/L,64.06 ± 8.11 U/L,38.14 ± 5.34 U/L,better than the control group,the difference was statistically significant(t= 5.247,P = 0.015;t= 6.347,P= 0.008;t = 6.137,P= 0.009 ;t= 4.995,P = 0.018);after treatment observation group's symptom score was 5.23 ± 0.67,significantly lower than the control group,the difference was statistically significant(t= 6.664,P= 0.007),in the observation group and the control group,portal vein diameter, splenic swelling index before and after treatment showed significant significance within group (P<0.05).Conclusion:Yiqi Huoxue Jiedu decoction treatment has significant clinical effect for chronic viral hepatitis B fibrosis patients,can significantly improve symptoms,worthy of clinical application.
